Welcome to Regulator, a newsletter for Verge subscribers about the technology and the tech bros upending American politics and the Trump administration. If you’re not a subscriber yet, and you’re interested in Silicon Valley’s adventures in sausage-making, you should do so here! It’s Q1! Surely the corporate budget will allow for it.

Precisely one year ago, Steve Bannon, the powerful, populist MAGA podcaster, was thrilled at the sight of the Big Tech CEOs swarming around Donald Trump. In the days before his inauguration, the major players were visiting Mar-a-Lago, signing checks, even showing up to sit quietly behind him during his second inauguration. For years, Bannon told ABC’s Jonathan Karl in an interview, Big Tech had undermined Trump: Jeff Bezos’ Washington Post had reported on him critically, for instance, while Meta and Alphabet’s subsidiaries had purportedly silenced his online presence. Now, Bannon said, they were “supplicants” to Trump, who’d hired MAGA regulators ready to tear apart those companies at any given moment. “Most people in our movement look at this as President Trump broke the oligarchs,” he bragged.

Even smaller pivots from firm MAGA positions in favor of the tech industry, and the response from said base, are telling. Last November, Trump sparked outrage from the right by defending the existence of H1-B visas for high-skilled foreign tech workers, going so far as to say that US workers lacked “certain talents” that prevented Big Tech from hiring domestically. Although Trump ended up radically overhauling the immigration lottery system in a more nativist favor, the continued existence of the H1-B visa program itself sparked a massive rift within the MAGAsphere: how could Trump let in any foreign workers, much less imply that they were better than American workers? What sort of “America First” was that?

For decades, even as a businessman, Trump’s had one consistent organizational principle: people and factions must constantly fight each other for his attention and favor. It happened all the time during Trump’s first term, when New York financiers, the Republican establishment, the career officials, Trump’s children, and the proto-MAGA wing were all fighting each other inside the West Wing. But by the time Trump returned to the campaign trail in 2024, the New Yorkers were exhausted and went home, the Republican establishment had caved to Trump, and the career officials were all about to be purged. MAGA populism had won, and they believed, to paraphrase Trump, that they would win so much that they would become tired of winning. It’s not like the populists haven’t claimed territory in Trump’s second administration. The Department of Justice is conducting lawfare against Trump’s critics, the Department of Homeland Security has given ICE a broadly terrifying mandate, and the Department of Defense (sorry, War) kidnapped a foreign head of state for the LOLs.

But honestly, I would not have expected a year ago, as I watched the tech CEOs applaud Trump in the Rotunda, that these “supplicants” would eventually sway Trump to their ways. I’m not sure how the next year looks for internal drama coming out of the White House. I will say, however, that it is very, very telling that Bannon, who once bragged that there was a plan in place for Trump to run for an unconstitutional third term, is reportedly eyeing a presidential run himself.

Well, in the sense of the Senate being on a one-week recess, during which I will be following the drama of Coinbase derailing the CLARITY Act over interest rates, before the Senate Banking Committee reconvenes. To my great regret, I am not at Davos, where CEO Brian Armstrong is and where most of the negotiations seem to be happening. So if you are in some private Swiss meeting with other tech overlords and have some insight into whether there will be an actual market structure bill passed in the upcoming year, please email me at tina@theverge.com, or over Signal at tina_nguyen.19.

For the first time, Americans with depression will soon be able to use a prescription brain-stimulation device at home. 

The approval comes from the U.S. Food and Drug Administration and marks a major shift in how mental health conditions may be treated. The newly approved device is called FL-100, and it comes from Flow Neuroscience. 

It is designed for adults 18 and older with moderate to severe major depressive disorder. Clinicians can prescribe it as a stand-alone treatment or alongside antidepressants and therapy. This decision matters because depression affects more than 20 million adults in the U.S. Roughly one-third do not get enough relief from medication or stop taking it due to side effects.

Sign up for my FREE CyberGuy Report
Get my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you’ll get instant access to my Ultimate Scam Survival Guide – free when you join my CYBERGUY.COM newsletter.

SIMPLE DAILY HABIT MAY HELP EASE DEPRESSION MORE THAN MEDICATION, RESEARCHERS SAY

How the Flow FL-100 works

The FL-100 uses transcranial direct current stimulation, often shortened to tDCS. This technology delivers a gentle electrical current to the prefrontal cortex, a region of the brain tied to mood regulation and stress response. In many people with depression, activity in this area is reduced. By stimulating it, the device aims to restore healthier brain signaling over time. The system looks like a lightweight headset and pairs with a mobile app. Patients use it at home for about 30 minutes per day while clinicians monitor progress remotely.

The clinical results behind the approval

The FDA based its decision on a randomized controlled trial that evaluated home use under remote supervision. Participants who received active stimulation showed meaningful improvement on clinician-rated and self-reported depression scales. After 10 weeks of treatment, patients experienced an average symptom improvement of 58% compared to a control group. Many users reported noticeable changes within the first three weeks. The study was published in the journal Nature Medicine, adding credibility to the findings. Side effects were generally mild and short-term. Reported issues included skin irritation, redness, headaches, and brief stinging sensations at the electrode sites.

A growing shift toward tech-based mental health care

Flow’s device has already been used by more than 55,000 people across Europe, the U.K., Switzerland and Hong Kong. In the U.K., it is prescribed within parts of the public health system. Company leaders say the U.S. approval opens the door for broader access to non-drug treatment options. The momentum is not isolated. In 2025, researchers at UCLA Health developed another experimental brain-stimulation approach, signaling rapid growth in this field. Together, these advances suggest that at-home neuromodulation may soon become a standard part of depression care rather than a fringe option.

When will the device be available

Flow expects the FL-100 to be available to U.S. patients in the second quarter of 2026. A prescription will be required, and the companion app will be available on iOS and Android. The company also plans to explore additional uses for its platform, including sleep disorders, addiction, and traumatic brain injury.

10 HEALTH TECH PRODUCTS STEALING THE SPOTLIGHT AT CES 2026

What to know before trying Flow

Flow is FDA approved for adults 18 and older with moderate to severe major depressive disorder, and it requires a prescription from a licensed healthcare provider. Doctors can recommend it on its own or alongside medication or therapy. The headset is non-invasive and designed for home use, but it is not meant for emergency situations or people considered treatment resistant. It also does not replace crisis care or immediate mental health support. Most users wear the headset for about 30 minutes per session. Mild tingling, warmth, skin irritation or headaches can happen, especially early on. These effects are usually short-lived and monitored by a clinician through the companion app.

Flow pairs with a mobile app that guides treatment and supports remote clinical oversight. Your provider sets the treatment plan, and the device follows prescribed settings to ensure safe use. Pricing and insurance coverage may vary once the device becomes available in the U.S. Some patients may access Flow through clinics, research programs, or as it becomes more widely adopted in routine depression care. The bottom line is simple. Flow adds another evidence-based option, not a cure and not a one-size-fits-all solution. For people who have struggled to find relief, having another clinically proven choice can matter a lot.

What this means to you

If you or someone you care about struggles with depression, this approval expands the range of real treatment options. It offers a non-drug path that can be used at home under medical guidance. For patients who have not responded well to medication or who experience unwanted side effects, this could provide another way forward. It also reflects a broader trend toward personalized, tech-enabled mental healthcare. 

Take my quiz: How safe is your online security?

Think your devices and data are truly protected? Take this quick quiz to see where your digital habits stand. From passwords to Wi-Fi settings, you’ll get a personalized breakdown of what you’re doing right and what needs improvement. Take my Quiz here: Cyberguy.com.

ELON MUSK SHARES PLAN TO MASS-PRODUCE BRAIN IMPLANTS FOR PARALYSIS, NEUROLOGICAL DISEASE

Kurt’s key takeaways

This FDA approval feels like a real turning point. For years, brain stimulation for depression stayed locked inside clinics. Now it can happen at home with a doctor still guiding the process. That matters for people who have tried medications, dealt with side effects or felt stuck with limited options. This device will not be the right answer for everyone, but it gives patients and doctors one more proven tool to work with. And for many people living with depression, having another option could make all the difference.

If a doctor could prescribe a brain-stimulation headset instead of another pill, would you be open to trying it? Let us know by writing to us at Cyberguy.com.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Sign up for my FREE CyberGuy Report
Get my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox. Plus, you’ll get instant access to my Ultimate Scam Survival Guide – free when you join my CYBERGUY.COM newsletter.

Copyright 2026 CyberGuy.com.  All rights reserved.

Christopher Klay, who previously developed the Stadia Enhanced browser extension, is one of many who saved a copy of the tool to a personal GitHub page. What’s more, they’re hosting a working copy of that Google website right here to make it even easier.